| Background:Osteosarcoma (OS) is the most common primary malignant tumor of bone in children and adolescents. However, the knowledge in diagnostic modalities and treatment methods is limited. To identify new biomarkers that facilitate the early diagnosis of OS and that maybe develop novel therapeutic candidates, we performed a subcellular comparative proteomic research. Methods:OS cell (MG-63) and human primary cultured osteoblastic cell (hFOB1.19) were used as a model. Plasma membrane (PM) was obtained by aqueous two-phase partition. Proteins were analyzed through iTRAQ-based quantitative differential LC/MS/MS. Results:342 non-redundant proteins were identified.63 were differentially expressed with 1.5-fold difference, with 10 up-and 53 down-regulated. For the differential proteins,69% ware plasma membrane. They are related to the biological processes of binding, cell structure, signal transduction, cell adhesion, etc., and are interacted with each other. One protein-CD151 located in net nodes was verified by Immnohistochemistry in osteosarcoma tissue of patients. Conclusion:It is the first time to use plasma membrane proteomics to study the OS membrane proteins according to our knowledge. CD151 might be a new biomarker for the diagnosis of OS and probably become a novel therapeutic candidate through further research. The plasma membrane proteins identified in this study may provide new insights into osteosarcoma cancer biology and potential diagnostic and treatment biomarkers. |
PDF Full Text Request